All > Prostate

Luteinizing Hormone Releasing Hormone for Prostate Cancer

Moffitt Cancer Center, Tampa, FL
Prostate Cancer+1 More ConditionsLuteinizing Hormone Releasing Hormone - Drug
Eligibility
18+
Male

Study Summary

This trial is testing a new way to treat high risk prostate cancer that may be more effective than current methods.

Eligible Conditions
  • Prostate Cancer
  • Advanced Prostate Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Similar Trials

1
BMS-986218 and Degarelix
1
Transdermal Testosterone
1
Lead-in phase: Darolutamide treatment

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: At 36 months

At 12 months
PSA <0.2 nanogram per milliliter (ng/ml) rate at 12 months
At 36 months
PSA <0.2 nanogram per milliliter (ng/ml) rate at 36 months
Radiographic Progression
At 6 months
PSA <0.2 nanogram per milliliter (ng/ml) rate at 6 months
Up to 36 months
Overall Survival
PSA Progression

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
BMS-986218 and Degarelix
1
Transdermal Testosterone
2
Lead-in phase: Darolutamide treatment

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

1 Treatment Group

First Strike then Second Strike
1 of 1

Experimental Treatment

31 Total Participants · 1 Treatment Group

Primary Treatment: Luteinizing Hormone Releasing Hormone · No Placebo Group · Phase 2

First Strike then Second StrikeExperimental Group · 4 Interventions: Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Tislelizumab, Docetaxel · Intervention Types: Drug, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tislelizumab
Not yet FDA approved
Docetaxel
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 36 months

Who is running the clinical trial?

BeiGeneIndustry Sponsor
154 Previous Clinical Trials
27,500 Total Patients Enrolled
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
514 Previous Clinical Trials
128,245 Total Patients Enrolled
26 Trials studying Prostate Cancer
3,653 Patients Enrolled for Prostate Cancer
Jingsong Zhang, MD, PhDPrincipal InvestigatorMoffitt Cancer Center
1 Previous Clinical Trials
26 Total Patients Enrolled
1 Trials studying Prostate Cancer
26 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Men from all different racial and ethnic backgrounds who meet the other requirements can participate in this study.
References

Frequently Asked Questions

What studies have been conducted using Luteinizing Hormone Releasing Hormone as an intervention?

"Presently, 643 trials are investigating the effects of Luteinizing Hormone Releasing Hormone. 209 of those clinical studies are Phase 3 and are concentrated in Germantown, Tennessee; however, there exist 38,624 locations that offer this treatment option." - Anonymous Online Contributor

Unverified Answer

How many participants are enrolled in this trial to its fullest extent?

"Affirmative. According to the information available on clinicaltrials.gov, this medical trial is currently recruiting patients - it was initially posted on January 25th 2022 and its most recent update came through November 28th 2022. It seeks 31 participants from a single medical centre." - Anonymous Online Contributor

Unverified Answer

To what afflictions is Luteinizing Hormone Releasing Hormone typically administered?

"Luteinizing Hormone Releasing Hormone is usually employed to combat malignant neoplasms, yet its efficacy can also be observed in therapeutic procedures, hypogonadotropic ovarian failure and sarcoma." - Anonymous Online Contributor

Unverified Answer

What is the federal regulatory stance on Luteinizing Hormone Releasing Hormone?

"Our team at Power rated Luteinizing Hormone Releasing Hormone with a score of 2. This is due to the medication being in Phase 2, meaning that it has some safety data but there are no efficacy studies yet conducted." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies for participants in this trial?

"Affirmative, the information archived on clinicaltrials.gov suggests that this experiment is currently enlisting volunteers. The trial was inaugurated on January 25th 2022 and its most recent update occurred November 28th 2022 - with a total of 31 participants being sought from one site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top